Design, synthesis and biological activity of 7-O-(4-O-acetyl-3-iodo-2,3,6-trideoxy-alpha-L-arabino-hexopyranosyl) daunomycinone and 7-O-(3-chloro-2,3,6-trideoxy-4-O-propanoyl-alpha-L-lyxo- hexopyranosyl)daunomycinone

Chem Pharm Bull (Tokyo). 2000 Jan;48(1):150-3. doi: 10.1248/cpb.48.150.

Abstract

The synthesis and pharmacological evaluation of 7-O-(4-O-acetyl-3-iodo-2,3,6-trideoxy-alpha-L-arabino-hexopyranosyl) daunomycinone and 7-O-(3-chloro-2,3,6-trideoxy-4-O-propanoyl-alpha-L-lyxo-hexopyrano syl) daunomycinone are described. Their cytotoxic activity was evaluated against normal and resistant cell lines. Both compounds exhibited activity against the adriamycin resistant cell line KB-A1. These results support the hypothesis that the increased lipophilicity of the sugar part of anthracyclines is associated with their ability to overcome multidrug resistance (MDR).

MeSH terms

  • Antibiotics, Antineoplastic / chemical synthesis*
  • Antibiotics, Antineoplastic / pharmacology
  • Cell Cycle / drug effects
  • Daunorubicin / analogs & derivatives*
  • Daunorubicin / chemical synthesis
  • Daunorubicin / pharmacology
  • Doxorubicin / pharmacology
  • Drug Design
  • Drug Screening Assays, Antitumor
  • Genes, MDR
  • Humans
  • Magnetic Resonance Spectroscopy
  • Tumor Cells, Cultured

Substances

  • 7-O-(3-chloro-2,3,6-trideoxy-4-O-propanoyl-lyxo-hexopyranosyl)daunomycinone
  • 7-O-(4-O-acetyl-3-iodo-2,3,6-trideoxy-arabino-hexopyranosyl)daunomycinone
  • Antibiotics, Antineoplastic
  • Doxorubicin
  • Daunorubicin